Literature DB >> 24426336

Chromosomal mosaicism for inversion of chromosome 3(p25, p26) in a case of idiopathic hypereosinophilic syndrome (IHES).

Nasim Valizadeh1.   

Abstract

Cytogenetic analysis and molecular genetic studies help for diagnosis of IHES and differentiation between IHES and other hematologic disorders with eosinophilia. We want to present a case of IHES with chromosomal mosaicism for inversion of chromosome 3(p25, p26), who achieved complete remission after treatment with Imatinib and short course of prednisolone.

Entities:  

Keywords:  Cytogenetic analysis; Idiopathic hypereosinophilic syndrome; Inversion

Year:  2011        PMID： 24426336      PMCID： PMC3572252          DOI： 10.1007/s12288-011-0131-x

Source DB:  PubMed          Journal:  Indian J Hematol Blood Transfus        ISSN： 0971-4502            Impact factor:   0.900


  10 in total

1.  Cytogenetic and molecular cytogenetic characterization of 6 new cases of idiopathic hypereosinophilic syndrome.

Authors:  R Bigoni; A Cuneo; M G Roberti; R Milani; A Bardi; F Cavazzini; C Minotto; G Castoldi
Journal:  Haematologica       Date:  2000-05       Impact factor: 9.941

Review 2.  The hypereosinophilic syndrome: analysis of fourteen cases with review of the literature.

Authors:  M J Chusid; D C Dale; B C West; S M Wolff
Journal:  Medicine (Baltimore)       Date:  1975-01       Impact factor: 1.889

3.  Evidence for the clonal nature of hypereosinophilic syndrome.

Authors:  M A da Silva; N Heerema; G R Schwenk; R Hoffman
Journal:  Cancer Genet Cytogenet       Date:  1988-05

4.  A combination of cytomorphology, cytogenetic analysis, fluorescence in situ hybridization and reverse transcriptase polymerase chain reaction for establishing clonality in cases of persisting hypereosinophilia.

Authors:  Ulrike Bacher; Andreas Reiter; Torsten Haferlach; Lothar Mueller; Susanne Schnittger; Wolfgang Kern; Claudia Schoch
Journal:  Haematologica       Date:  2006-06       Impact factor: 9.941

5.  A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome.

Authors:  Jan Cools; Daniel J DeAngelo; Jason Gotlib; Elizabeth H Stover; Robert D Legare; Jorges Cortes; Jeffrey Kutok; Jennifer Clark; Ilene Galinsky; James D Griffin; Nicholas C P Cross; Ayalew Tefferi; James Malone; Rafeul Alam; Stanley L Schrier; Janet Schmid; Michal Rose; Peter Vandenberghe; Gregor Verhoef; Marc Boogaerts; Iwona Wlodarska; Hagop Kantarjian; Peter Marynen; Steven E Coutre; Richard Stone; D Gary Gilliland
Journal:  N Engl J Med       Date:  2003-03-27       Impact factor: 91.245

Review 6.  The FIP1L1-PDGFRalpha fusion tyrosine kinase in hypereosinophilic syndrome and chronic eosinophilic leukemia: implications for diagnosis, classification, and management.

Authors:  Jason Gotlib; Jan Cools; James M Malone; Stanley L Schrier; D Gary Gilliland; Steven E Coutré
Journal:  Blood       Date:  2003-11-20       Impact factor: 22.113

7.  Chromosomal aneuploidy in a patient with hypereosinophilic syndrome. Evidence for a malignant disease.

Authors:  J D Bitran; J D Rowley; F Plapp; H M Golomb; J E Ultmann
Journal:  Am J Med       Date:  1977-12       Impact factor: 4.965

8.  FIP1L1-PDGFRA fusion: prevalence and clinicopathologic correlates in 89 consecutive patients with moderate to severe eosinophilia.

Authors:  Animesh Pardanani; Stephanie R Brockman; Sarah F Paternoster; Heather C Flynn; Rhett P Ketterling; Terra L Lasho; Ching-Liang Ho; Chin-Yang Li; Gordon W Dewald; Ayalew Tefferi
Journal:  Blood       Date:  2004-07-29       Impact factor: 22.113

Review 9.  Further evidence for the clonal nature of the idiopathic hypereosinophilic syndrome: complete haematological and cytogenetic remission induced by interferon-alpha in a case with a unique chromosomal abnormality.

Authors:  M L Malbrain; H Van den Bergh; P Zachée
Journal:  Br J Haematol       Date:  1996-01       Impact factor: 6.998

10.  Hypereosinophilic syndrome: a multicenter, retrospective analysis of clinical characteristics and response to therapy.

Authors:  Princess U Ogbogu; Bruce S Bochner; Joseph H Butterfield; Gerald J Gleich; Johannes Huss-Marp; Jean Emmanuel Kahn; Kristin M Leiferman; Thomas B Nutman; Florian Pfab; Johannes Ring; Marc E Rothenberg; Florence Roufosse; Marie-Helene Sajous; Javed Sheikh; Dagmar Simon; Hans-Uwe Simon; Miguel L Stein; Andrew Wardlaw; Peter F Weller; Amy D Klion
Journal:  J Allergy Clin Immunol       Date:  2009-12       Impact factor: 10.793
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.